Temporal changes in mediation effects on cardiovascular and microvascular outcomes with glucagon-like peptide-1 receptor agonist therapy: a post-hoc analysis of the LEADER trial

被引：0
|
作者：
Peng, Zi-Yang [1 ]
Lee, Yu-Hsuan [1 ]
Ou, Huang-Tz [1 ,2 ]
Kuo, Shihchen [1 ,3 ]
机构：
[1] Natl Cheng Kung Univ, Inst Clin Pharm & Pharmaceut Sci, Coll Med, 1 Univ Rd, Tainan 701, Taiwan
[2] Natl Cheng Kung Univ, Coll Med, Dept Pharm, 1 Univ Rd, Tainan 701, Taiwan
[3] Univ Michigan, Div Metab Endocrinol & Diabet, Dept Internal Med, Med Sch, 24 Frank Lloyd Wright Lobby C,Suite 1300, Ann Arbor, MI 48106 USA
来源：
CARDIOVASCULAR RESEARCH | 2024年
关键词：
LIRAGLUTIDE;
D O I：
10.1093/cvr/cvae237
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Practical applications of therapy with a glucagon-like peptide-1 receptor agonist
    Shomali, Mansur E.
    JOURNAL OF FAMILY PRACTICE, 2009, 58 (09): : S35 - S43
  • [2] Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
    Kang, Yu Mi
    Jung, Chang Hee
    ENDOCRINOLOGY AND METABOLISM, 2016, 31 (02) : 258 - 274
  • [3] Cardiovascular effects of glucagon-like peptide-1 receptor agonist therapies in patients with type 1 diabetes
    Rizzo, Manfredi
    Rizvi, Ali A.
    Sesti, Giorgio
    DIABETES OBESITY & METABOLISM, 2017, 19 (05): : 613 - 614
  • [4] Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL
    Torekov, Signe Sorensen
    CARDIOVASCULAR RESEARCH, 2018, 114 (10) : E70 - E71
  • [5] Glucagon-like peptide-1 receptor agonist and the relation between metabolic effects and cardiovascular outcomes: insight into mechanisms of action
    Di Ienno, L.
    Serenelli, M.
    De Carolis, B.
    Cantone, A.
    Buccino, N.
    Tolomeo, P.
    Vitali, F.
    Guardigli, G.
    Campo, G.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2956 - 2956
  • [6] Potential Cardiovascular Effects of the Glucagon-like Peptide-1 Receptor Agonists
    Chilton, Robert J.
    JOURNAL OF DIABETES & METABOLISM, 2015, 6 (01)
  • [7] Cardiovascular outcomes of glucagon-like peptide-1 agonist in patients with obesity and hypertrophic cardiomyopathy
    Fath, Ayman R.
    Aglan, Amro
    Maron, Martin S.
    Phillips, Jason S.
    Maron, Barry J.
    Rowin, Ethan J.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2025, 426
  • [8] Cardiovascular and hemodynamic effects of glucagon-like peptide-1
    Adam G. Goodwill
    Kieren J. Mather
    Abass M. Conteh
    Daniel J. Sassoon
    Jillian N. Noblet
    Johnathan D. Tune
    Reviews in Endocrine and Metabolic Disorders, 2014, 15 : 209 - 217
  • [9] Glucagon-Like Peptide-1 and its Cardiovascular Effects
    Kyung-Sun Heo
    Keigi Fujiwara
    Jun-ichi Abe
    Current Atherosclerosis Reports, 2012, 14 : 422 - 428
  • [10] Glucagon-Like Peptide-1 and its Cardiovascular Effects
    Heo, Kyung-Sun
    Fujiwara, Keigi
    Abe, Jun-ichi
    CURRENT ATHEROSCLEROSIS REPORTS, 2012, 14 (05) : 422 - 428
12345